Paniz Tavakoli Shirazi

Paniz Tavakoli Shirazi

Auto-generated profile, based on publicly available information

Paniz Tavakoli Shirazi

Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

12 January 2022 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
PSPaniz Tavakoli Shirazi
Paniz Tavakoli Shirazi
LELaura N. Eadie
Laura N. Eadie
SHSusan Heatley
Susan Heatley
Elyse C. PageElyse C. Page
Elyse C. Page
MFMaxime François
Maxime François
Deborah L WhiteDeborah L White
Deborah L White

8 June 2026 in bioRxiv
Verified
Preprint
Open access
PSPaniz Tavakoli Shirazi
Paniz Tavakoli Shirazi
JSJasmin Straube
Jasmin Straube
VLVictoria Ling
Victoria Ling
SAStacey Andersen
Stacey Andersen
ECEmily Cooper
Emily Cooper
SLSteven Lane
Steven Lane
Concurrent mutations in DNMT3A, NPM1, and FLT3 define a high-risk subtype of acute myeloid leukemia (AML) associated with increased relapse risk and inferior survival following standard chemotherapy. However, the mechanisms by which DNMT3A mutations promote treatment resistance in NPM1c-FLT3ITD AML remain unclear. Using genetically engineered murine models of Npm1c-Flt3ITD AML with or without Dnmt3aR878H (homologous to human DNMT3AR882H), we demonstrate that Dnmt3aR878H promotes chemotherapy resistance through epigenetic regulation of leukemia stem cell (LSC) quiescence. Integrated transcriptomic and epigenetic profiling revealed coordinated remodeling of DNA methylation and chromatin accessibility in LSC-enriched populations, characterized by preferential hypomethylation and increased accessibility at loci associated with stemness and quiescence programs. These data were confirmed in human DNMT3AR882H-NPM1c-FLT3ITD AML datasets with enrichment of quiescence-associated and stem cell enriched transcriptional programs. Conversely, Dnmt3a-mutant LSCs retained sensitivity to the cell-cycle independent regimen venetoclax plus azacitidine, but residual LSCs exhibited transcriptional plasticity and reversion to a de-differentiated state. We have identified LSC heterogeneity spanning primitive hematopoietic stem cell (HSC)-and progenitor-like states and our data demonstrate preferential maintenance of a quiescent HSC-like LSC subpopulation in Dnmt3aR878H-mutant AML following chemotherapy treatment. Pharmacologic induction of cell-cycle entry using pegylated interferon α (pegIFNα) disrupted the quiescent LSC state and restored chemotherapy sensitivity, identifying quiescence as a reversible and therapeutically actionable mechanism of resistance. These findings identify DNMT3A-mediated epigenetic regulation of LSC quiescence as a conserved mechanism of standard chemotherapy resistance and position therapeutic reactivation of quiescent LSCs as a promising strategy to overcome chemotherapy resistance and improve outcomes in high-risk DNMT3A-mutant AML.